Cell Source

Executive Summary

Cell Source, Inc. is a private Israeli biotech developing Veto Cell-based immunotherapies designed to induce selective immune tolerance. The company's platform combines allogeneic stem-cell transplantation with engineered T-cells (Veto Cells) that prevent graft rejection and graft-versus-host disease, while also integrating CAR-T cancer targeting with Veto Cell persistence to enhance oncology outcomes. Currently in Phase 1 development, Cell Source addresses critical challenges in transplantation and oncology by reducing reliance on immunosuppressants and improving the safety and efficacy of cell therapies. With a lean team of 10-50 employees and a focused R&D pipeline, the company is positioned to advance its novel platform through early clinical proof-of-concept. Key upcoming catalysts include the initiation of its first-in-human Phase 1 trial, which could provide initial safety and efficacy data, and potential partnering discussions to secure non-dilutive funding or strategic alliances. While still at an early stage, Cell Source's differentiated approach to immune tolerance and CAR-T therapy offers a compelling value proposition in the competitive cell therapy landscape.

Upcoming Catalysts (preview)

• Q2 2027Initiation of Phase 1 Clinical Trial40% success
• Q4 2026Preclinical Proof-of-Concept Data Publication60% success
• Q1 2027Strategic Partnership or Licensing Deal30% success